meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
first booster dose
mRNA vaccine (any) - first boost
Comirnaty - first boost
Spikevax - first boost
Non replicating viral vector -first boost
Vitamins
potential COVID-19 treatments
control
vaccines
complete primary vaccine series
mRNA vaccine
Comirnaty (tozinameran - Pfizer/BIONTECH)
Spikevax (Moderna mRNA-1273 COVID-19 vaccine)
Non replicating viral vector
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
age >= 55 yr
age >= 60 yr
age >= 65 yr
delta variant (B.1.617.2, Indian)
elderly (typically over 65yr)
immunodepression
omicron variant BA.1 (B.1.1.529)
omicron variant BA.2 VOC
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded